Ling Chen, Fangyu Dai, Wanhua Hu, Kelong Chen, Zhimin Wu, Yuting Zhang, Rong Zhou
Department of Neurology, Wenzhou Hospital of Traditional Chinese Medicine Affiliated to Zhejiang Chinese Medicine University, Zhejiang, PR China.
Department of Neurology, Zhoushan Hospital, Zhejiang, PR China.
Am J Alzheimers Dis Other Demen. 2016 May;31(3):278-81. doi: 10.1177/1533317515603688. Epub 2015 Sep 14.
Alzheimer's disease (AD) is classified as a neurodegenerative disease, impacting on brain integrity and functioning, resulting in a progressive deterioration of cognitive capabilities. Epigenetic changes can be acquired over the life span and mediate environmental effects on gene expression. DNA-methyltransferase 3A (DNMT3A) plays an important role in the development of embryogenesis and the generation of aberrant methylation late-onset AD (LOAD). In this study, the rs1550117 polymorphism of DNMT3A was determined by polymerase chain reaction/restriction fragment length polymorphism and confirmed by sequencing. The results showed that AA genotype carriers had a 2.08-fold risk of developing LOAD in comparison with GG genotype carriers (odds ratio [OR] = 2.08, 95% confidence interval [CI]: 1.03-4.21,P= .038) and had a 2.05-fold risk for LOAD compared with GG+GA genotype carriers (OR = 2.05, 95% CI: 1.03-4.11,P= .038), indicating that the DNMT3A polymorphism supports a major role in the pathogenesis of LOAD and can be used as a stratification marker to predict an individual's susceptibility to LOAD.
阿尔茨海默病(AD)被归类为一种神经退行性疾病,会影响大脑的完整性和功能,导致认知能力逐渐衰退。表观遗传变化可在整个生命周期中获得,并介导环境对基因表达的影响。DNA甲基转移酶3A(DNMT3A)在胚胎发育以及晚发性阿尔茨海默病(LOAD)异常甲基化的产生过程中发挥重要作用。在本研究中,通过聚合酶链反应/限制性片段长度多态性方法确定了DNMT3A的rs1550117多态性,并通过测序进行了验证。结果显示,与GG基因型携带者相比,AA基因型携带者患LOAD的风险高出2.08倍(优势比[OR]=2.08,95%置信区间[CI]:1.03 - 4.21,P = .038);与GG + GA基因型携带者相比,AA基因型携带者患LOAD的风险高出2.05倍(OR = 2.05,95% CI:1.03 - 4.11,P = .038),这表明DNMT3A多态性在LOAD发病机制中起主要作用,可作为预测个体患LOAD易感性的分层标志物。